Sita Dosage/Direction for Use

The recommended dose of Sitagliptin is 100 mg once daily as monotherapy or as combination therapy with metformin, a sulfonylurea, a PPARγ agonist (i.e., thiazolidinediones), metformin plus a sulfonylurea, or metformin plus a PPARγ agonist. Sitagliptin can be taken with or without food. When Sitagliptin is used in combination with a sulfonylurea, a lower dose of sulfonylurea may be considered to reduce the risk of sulfonylurea-induced hypoglycaemia. If a dose of Sitagliptin is missed, it should be taken as soon as the patient remembers. A double dose Sitagliptin should not be taken on the same day.
Patients with Renal Insufficiency: Mild renal insufficiency: For patients with mild renal insufficiency (creatinine clearance [CrCl ≥50 mL/min), no dosage adjustment is required.
Moderate renal insufficiency: For patients with moderate renal insufficiency (CrCl ≥30 to <50 mL/min), the dose of Sitagliptin is 50 mg once daily.
Severe renal insufficiency: For patients with severe renal insufficiency (CrCl <30 mL/min) or with end-stage renal disease (ESRD) requiring haemodialysis or peritoneal dialysis, the dose of Sitagliptin is 25 mg once daily. Sitagliptin may be administered without regard to the timing of haemodialysis. Because there is a dosage adjustment based upon renal function, assessment of renal function is recommended prior to initiation of Sitagliptin and periodically thereafter.
Patients with Hepatic Insufficiency: No dosage adjustment is necessary for patients with mild to moderate hepatic insufficiency.
Sitagliptin has not been studied in patients with severe hepatic insufficiency.
Elderly: No dosage adjustment is necessary for elderly patients.
Paediatric Population: There are no data available on the use of Sitagliptin in patients younger than 18 years of age.